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Abstract: Advances in our understanding of the pathophysiology of migraine have resulted 
in important breakthroughs in treatment. For example, understanding of the role of serotonin 
in the cerebrovascular circulation has led to the development of triptans for the acute relief of 
migraine headaches, and the identiﬁ  cation of cortical spreading depression as an early central 
event associated wih migraine has brought renewed interest in antiepileptic drugs for migraine 
prophylaxis. However, migraine still remains inadequately treated. Indeed, it is apparent that 
migraine is not a single disease but rather a syndrome that can manifest itself in a variety of 
pathological conditions. The consequences of this may be that treatment needs to be matched 
to particular patients. Clinical research needs to be devoted to identifying which sort of patients 
beneﬁ  t best from which treatments, particularly in the ﬁ  eld of prophylaxis. We propose four 
patterns of precipitating factors (adrenergic, serotoninergic, menstrual, and muscular) which 
may be used to structure migraine prophylaxis. Finally, little is known about long-term outcome 
in treated migraine. It is possible that appropriate early prophylaxis may modify the long-term 
course of the disease and avoid late complications.
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Migraine headaches are the most frequent type of incapacitating headache and one of 
the most common reasons for consultation in neurology. However, these headaches 
have historically been poorly understood in terms of natural history, pathophysiology 
and prognosis. This unsatisfactory state of affairs had important consequences for the 
diagnosis and treatment of migraine, which have been frequently inadequate. Indeed, 
the ﬁ  rst rational classiﬁ  cation of headache semiology, providing an unambiguous 
deﬁ  nition of migraine was established relatively recently by the International Headache 
Society in 1988 (HCCIHS 1988) (revised in 2004 [HCCIHS 2004]). This provides a 
framework for the standardized diagnosis of migraine.
For this reason, there is little available data on long-term disease course from 
natural history cohorts which have used this diagnosis classiﬁ  cation. In particular, 
although headache relief treatments, often with over-the-counter analgesic drugs, 
are widely used, the long-term management of migraine, involving prophylactic 
treatments and the implementation of strategies to prevent headache evolution to 
more severe disease and to promote remission, has been explored relatively little. 
This situation has changed somewhat over recent years with the introduction of 
standardized guidelines for the diagnosis and treatment of migraine headaches. 
Moreover, the introduction of triptans as a speciﬁ  c treatment for relief of migraine 
headaches has stimulated much research into the biology of migraine, leading to 
a better understanding of its pathophysiology. This articles reviews recent devel-
opments in our understanding of migraine and their consequences for improved 
management of migraine as a chronic disease.Therapeutics and Clinical Risk Management 2008:4(5) 1062
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Natural history of migraine
Migraine headache generally presents for the ﬁ  rst time during 
adolescence, with a lower mean age of onset in males than in 
females (Ulrich et al 1999). However, migraine does occur in 
younger children (Abu-Arefeh and Russell 1994; Annequin 
et al 2000) and may be under-diagnosed due to difﬁ  culties in 
assessing accurately symptomatology in this population.
There have been few longitudinal studies investigating 
long-term outcome of migraine headache. However, given 
that the prevalence of migraine decreases with age, it can 
be expected that, in many cases, these headaches resolve 
spontaneously. Two recent studies have evaluated long-term 
outcome in larger populations whose original migraine diag-
nosis was established using the IHS criteria. The ﬁ  rst study 
followed up 549 of 740 subjects originally diagnosed with 
episodic headaches in 1989 (Lyngberg et al 2005). Twelve 
years after the original diagnosis, 42% of subjects were in 
remission, 38% had less frequent headaches and 20% had 
more frequent headaches. Poor outcome was associated 
with high migraine frequency at baseline and age at onset 
younger than 20 years. For tension-type headache, remission 
was observed in 45% of subjects and transformation into a 
chronic tension-type headache was reported in 16%. The 
second study evaluated 1250 of 2051 subjects originally 
identiﬁ  ed in 2003, of whom 398 fulﬁ  lled diagnostic criteria 
for migraine (Nachit-Ouinekh et al 2005). Ten years later, 
37% stilled fulﬁ  lled these criteria, whereas 36% now fulﬁ  lled 
diagnostic criteria for migrainous disorder and 18% for other 
episodic headache types, the remainder being in complete 
remission. Remission or evolution to a less severe headache 
was more frequent in men and in older subjects.
Chronic headache presentations
These longitudinal studies identify a minority of subjects 
whose condition deteriorates with time, notably with an 
increased frequency of headaches. This corresponds to the 
notion of transformed migraine (Mathew et al 1982) or 
chronic daily headache. Many of these headaches may be 
iatrogenic and high levels of analgesic drug use have been 
described in up to three-quarters of cases (Mathew 1997) 
and are associated with a risk of transformation (Zwart 
et al 2003; Dowson et al 2005). Although analgesic drugs 
have been implicated most frequently in the development 
of chronic daily headaches, recent studies suggest that use 
of speciﬁ  c acute migraine treatments (triptans) may also 
lead to transformation of migraine (Limmroth et al 2002). 
High caffeine use has also been described as a risk factor for 
transformation (Scher et al 2004). Psychiatric comorbidity, 
notable depression, may also be associated with an increased 
risk of transformation (Mathew 1997; Wang et al 2000).
In addition, tension-type headaches may also evolve into 
a chronic form. Chronic tension-type headaches, as deﬁ  ned 
in the IHS classiﬁ  cation, occur with a frequency of over 
180 days per year and are distinguished from transformed 
migraine (or chronic daily headache with migrainous 
features) by their characteristic symptom presentation (steady 
rather than pulsatile pain, bilateral rather than unilateral, etc). 
Some characteristic features of migraine, such as nausea, 
are less prevalent in subjects with chronic daily headache 
than in those with classical migraine headache (Solomon 
et al 1992; Mathew 1993; Lanteri-Minet et al 2003). The 
overall prevalence of chronic daily headache in the general 
population is around 4% (Wang et al 2000; Scher et al 1998; 
Castillo et al 1999; Lanteri-Minet et al 2003), with most 
studies reporting chronic tension-type headache to be more 
frequent than transformed migraine. Individuals presenting 
with these headache types represent a large segment of the 
population consulting specialist headache centres. Chronic 
daily headaches often remit spontaneously, and a one-year 
remission rate of 14% has been estimated from a general 
population sample (Scher et al 2003). Factors associated with 
a poor prognosis of chronic daily headache include older age, 
long duration of chronic headaches and medication overuse 
(Wang et al 2000; Lu et al 2001).
Consequences for treatment
The long-term outcome of migraine can thus be variable 
(Figure 1) and it is an important objective of therapy to 
ensure a favorable outcome (remission). This raises a 
number of important questions. Classical migraine can be 
managed effectively with acute or prophylactic treatments 
(see below) although analgesic drugs should be avoided as 
headache relief medication in order to reduce the risk of 
transformation to a chronic headache type. Certain of these 
drugs may be acquired over the counter and used as self-
medication, and it is important to identify and discourage 
such habits in patients consulting for migraine headache. 
In patients whose headaches have already transformed into 
a chronic presentation, medication withdrawal can in many 
cases be sufﬁ  cient to promote remission (Linton-Dahlof et al 
2000; Kavuk et al 2004).
Migrainous disorder can be considered as a ‘mild’ form 
of classical migraine and clinical experience suggests that 
these headaches respond to the same relief medications as the 
latter disorder, although this has not been evaluated speciﬁ  -
cally in randomized clinical trials. A methodical evaluation Therapeutics and Clinical Risk Management 2008:4(5) 1063
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of symptoms is recommended in order to distinguish these 
headaches from tension-type headaches and to treat them 
appropriately.
It is not clear whether tension-type headache that is 
secondary to migraine headache (‘burnt-out’ migraine) 
differs from primary tension-type headaches in their 
physiopathology and in their response to treatments. 
For example, two randomized clinical trials have shown 
sumatriptan to be inefﬁ  cacious in primary tension-type 
headaches (Brennum et al 1996; Lipton et al 2000a) but their 
utility in secondary tension-type headaches evolving from 
migraine is unknown.
Another important unanswered question relates to 
whether early and intensive drug treatment of migraine 
headaches changes the probability of a favorable outcome. 
In another paroxystic neurological disorder, epilepsy, this is 
an established therapeutic principle, and merits investigation 
in long-term follow-up studies of patients presenting with 
and treated for migraine headaches.
Migraine as a syndrome
It is increasingly apparent that migraine is best understood as 
a syndrome expressed in several different subtypes of underly-
ing disease. These various subtypes differ in their symptom 
presentation and are also likely to respond better to certain 
treatments than to others. A major challenge is to identify the 
most appropriate treatments for each subtype of migraine.
Familial hemiplegic migraine is probably only the ﬁ  rst 
form of familial migraine whose genetic basis has been 
elucidated. This form of migraine headache can be con-
sidered a channelopathy in which symptoms arise due to a 
change in the gating kinetics of P/Q type calcium channels 
brought about by the mutations (Kraus et al 1998, 2000). The 
consequence of this may be an impairment of local GAB-
Aergic inhibitory circuits (Cao and Tsien 2005). It may also 
be possible to deﬁ  ne subtypes of migraine headache based 
on differences in precipitating factors. First of all, stress-
induced headache, mediated by an adrenergic mechanism 
may be a speciﬁ  c migraine subtype. Stress is the most fre-
quently cited precipitating factor and related to a particular 
pattern of physiological activation, namely activation of 
the hypothalamo-pituitary-adenocortical axis and increased 
sympathetic tone. This may lead to increased vasoconstrictor 
tone in the cerebral vasculature and thus sensitize individuals 
to migraine headache.
Mood and sleep disturbances are also common 
precipitating factors for migraine and these are associated 
with the central serotonergic system. Another group of 
precipitating factors relates to sensory stimuli such as 
particular smells (tobacco or perfume) or foodstuffs (cheese, 
alcohol, chocolate) and these may also implicate serotonergic 
mechanisms.
Menstrual migraine provides an example of a form of 
migraine with a speciﬁ  c precipitating factor, pathogenesis 
Migraine Transformed migraine 
Migrainous disorder
Tension-type headache Chronic tension-type 
headache
Remission
Figure 1 Potential long-term course of migraine headaches.Therapeutics and Clinical Risk Management 2008:4(5) 1064
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and treatment. Around half of women with migraine report 
menstruation to be a precipitating factor (Henry et al 
2002; Zivadinov et al 2003) and the frequency of migraine 
attacks varies over the reproductive cycle (Granella et al 
1993). A recent large prospective survey in a population 
of 153 women with migraine (MacGregor 2004) identiﬁ  ed 
a relative risk of migraine headache of 1.7 in the two days 
preceding menstruation and of 2.3 in the ﬁ  rst three days of 
menstruation compared to all other times of the cycle. Men-
strual migraine attacks have been reported to be of longer 
duration and to be more incapacitating than non-menstrual 
migraine (Couturier et al 2003; Granella et al 2004).
In women with ‘pure’ menstrual migraine (ie, those who 
only have headache attacks at the onset of menstruation and 
not at other times of the cycle), the onset of headache has 
been associated with rapidly falling plasma concentrations of 
estrogen (Somerville 1972). Indeed, women with menstrual 
migraine show larger swings in estrogen levels across the 
menstrual cycle than did women without menstrual migraine 
(Epstein et al 1975). Estrogen challenge experiments have 
shown that migraine can be precipitated following artiﬁ  cial 
elevations of plasma estrogen levels both in women with 
active menstrual migraine (Somerville 1975) and in post-
menopausal women with antecedents of menstrual migraine 
(Lichten et al 1996; Facchinetti et al 2002). This hypothesis is 
also supported by the observation that women taking oral con-
traceptives often experience headache during the estrogen-free 
week and by reports of emergent migraine in women interrupt-
ing hormone replacement therapy (MacGregor 2004). Exactly 
how ﬂ  uctuations in estrogen levels trigger headache is, on 
the other hand, far from clear. Estrogens have a number of 
effects on the nervous system involving both genomic actions 
and direct effects on neuronal excitability (McEwen 2001). 
These latter may sensitize the nervous system to cortical 
spreading depression or modify gating of nociceptive stimuli 
in the trigeminal nucleus. Studies in experimental animals 
have provided evidence for a change in the sensitivity of the 
GABAA receptor over the course of the estrous cycle (Carey 
et al 1992; Diaz-Veliz et al 2000). It should also be pointed out 
that estrogens have direct effects on the cerebral vasculature 
(Littleton-Kearney et al 2000) which may also contribute to 
the occurrence of migraine headaches. Menstrual migraine 
can be treated not only with headache medication active in all 
types of migraine, but also with speciﬁ  c hormonal treatments 
aimed at attenuating estrogen withdrawal (Loder et al 2005). 
These are described in more detail below.
Finally, certain otherwise typical pulsatile migraine 
headaches may share features typical of tension-type 
headaches such as a sensation of muscular pressure or 
tension, and represent a mixed headache type. These 
headaches generally localise to the posterior occipital cortex 
and have a high probability of transformation into a chronic 
headache type. Whether such headaches are a transition 
stage in the deteriorating course of certain classical migraine 
headaches or represent a subtype of migraine with a distinct 
aetiopathology is unclear, but they are frequently associated 
with muscular diseases like ﬁ  bromyalgia.
A proposed classiﬁ  cation of migraine headaches based 
on triggering factors is presented in Figure 2. The case of 
menstrual migraine, where a speciﬁ  c prophylaxis can be 
proposed may illustrate a general principle, and it will be 
interesting to see whether other prophylactic treatments 
may be particularly effective in migraineurs with particular 
patterns of precipitating factors. For example, beta-blockers 
such as propranolol, or alpha-blockers such as indoramine 
may be particularly effective in Type A migraine (as deﬁ  ned 
in Figure 2) whereas antiserotonergic drugs such as methyser-
gide, dihydroergotamine or pizotofen may be more effective 
in Type B migraine. Hormone therapy is clearly useful in 
Type C (see below), and muscle relaxant and antidepressant 
drugs like amitriptyline seem effective in Type D, associated 
with other prophylactic migraine treatments where neces-
sary. Adequately designed randomized clinical trials will 
be required to test these hypotheses. Of course, in medical 
practice patients presenting features typical of more than one 
headache type are frequently encountered. In these cases, the 
optimal therapeutic strategy may require association of two 
or three of these drugs.
Acute treatment of migraine 
headaches
Four classes of drug are used as acute treatments for the relief 
of headache. Nonsteroidal antiinﬂ  ammatory drugs (NSAIDs) 
and analgesics represent non-speciﬁ  c headache relief medica-
tions and the triptans and ergot alkaloids migraine-speciﬁ  c 
treatments. NSAIDs are generally preferred to analgesics as 
non-speciﬁ  c treatments, since the latter drugs have a high 
perceived risk of leading to the development of chronic 
medication-overuse headaches (Zwart et al 2003). However, 
all acute treatments may to a greater or lesser extent lead to 
medication overuse headache and prophylactic treatments 
should be used in patients with frequent headaches to reduce 
headache frequency and thus recourse to acute medication. 
Triptans have come to supersede ergot alkaloids as speciﬁ  c 
headache relief treatments in many countries as they are 
perceived to have superior tolerability and efﬁ  cacy.Therapeutics and Clinical Risk Management 2008:4(5) 1065
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Various treatment strategies for headache relief  have been 
proposed that combine these drug classes in which patients 
initially take a non-speciﬁ  c treatment and then add a triptan, 
ﬁ  rst-line/second-line strategies in which patients are initially 
prescribed an NSAID and then switched to a triptan in case of 
non-response, and stratiﬁ  ed care, in which NSAIDs or triptans 
are differentially prescribed according to headache severity.
Non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) are 
widely used for acute headache relief both as prescription and 
over-the-counter medication (Lucas et al 2005). Numerous 
clinical trials of varying quality have been performed with 
these agents since the 1960’s.
Placebo-controlled trials have shown aspirin to be effec-
tive in the relief of migraine headache, either used alone 
(Boureau et al 1994; Lange et al 2000; MacGregor et al 2002; 
Lipton et al 2005b), in combination with metoclopramide 
(Chabriat et al 1994; Tfelt-Hansen et al 1995; Henry et al 
1995) or in combination with paracetamol and caffeine 
(Lipton et al 1998). Data from placebo-controlled trials sug-
gests efﬁ  cacy for ibuprofen (Kloster et al 1992; Nebe et al 
1995; Sandrini et al 1998; Kellstein et al 2000; Codispoti 
et al 2001), including two studies in children (Hamalainen 
et al 1997; Lewis et al 2002). Diclofenac has proved superior 
to placebo in several trials (Massiou et al 1991; Dahlof and 
Bjorkman 1993; The Diclofenac-K/Sumatriptan Migraine 
Study Group 1999; Peroutka et al 2004). An important 
advantage of diclofenac appears to be its rapidity of action. 
An intramuscular injectable form is also available and been 
shown to provide rapid headache relief (Karachalios et al 
1992; Bigal et al 2002). Ketoprofen has been compared to 
placebo in a larger study using a standard oral formulation 
(Dib et al 2002). This study demonstrated superior efﬁ  cacy 
for ketoprofen.
Comparative trials with triptans have been performed 
for oral aspirin compared to oral sumatriptan (Diener 
et al 2004a), oral aspirin and metoclopramide compared 
to oral sumatriptan (The Oral Sumatriptan and Aspirin 
plus Metoclopramide Comparative Study Group 1992; 
Tfelt-Hansen et al 1995), intravenous aspirin compared to 
subcutaneous sumatriptan (Diener 1999), oral aspirin and 
metoclopramide compared to oral zolmitriptan (Geraud et al 
2002), oral ibuprofen compared to oral sumatriptan (Diener 
et al 2004a), oral diclofenac versus oral sumatriptan (The 
Diclofenac-K/Sumatriptan Migraine Study Group 1999), 
oral naproxen versus oral naratriptan (Stronks et al 2003), 
oral tolfenamic acid versus oral sumatriptan (Myllyla et al 
1998) and oral ketoprofen versus oral zolmitriptan (Dib 
et al 2002). With the exception of the asprin/zolmitriptan 
and noproxen/naratriptan studies, all these trials showed 
comparable efﬁ  cacy for the NSAID and the triptan in most, 
if not all, endpoints. Figure 3 presents data on headache 
relief at two hours from the ketoprofen/zolmitriptan study. 
Given the comparable efﬁ  cacy of NSAIDs to triptans and 
the considerably lower cost of the latter, many treatment 
guidelines suggest the use of an NSAID as ﬁ  rst-line treatment 
for migraine headache.
Type A  Migraine
• Stress-related
• Adrenergic
component?
Type B  Migraine
• Triggered by  
mood, sleep or 
sensory-related 
factors
• Serotonergic
component?
Type C  Migraine
• Menstrual 
migraine
• Oestrogen-related
Type D  Migraine
• No specific trigger 
• Resembles TTH
• Muscular
component?
Figure 2  A classiﬁ  cation of migraine headaches based on triggering factors.Therapeutics and Clinical Risk Management 2008:4(5) 1066
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Triptans
The introduction of the triptans as speciﬁ  c treatments for 
migraine headache represented an important breakthrough 
as these drugs were both more efﬁ  cacious and better toler-
ated than previously available drugs (ergot alkaloids). The 
ﬁ  rst demonstration of the potential beneﬁ  t of triptans came 
from an open-label proof-of-concept study published in 
1988 (Doenicke et al 1988), subsequently conﬁ  rmed in two 
pivotal randomized controlled trials (Ensink 1991). Sumat-
riptan was ﬁ  rst made available as an injectable subcutaneous 
formulation in 1992 and subsequently as oral tablets and as a 
nasal spray. Since the introduction of sumatriptan, six other 
members of this class have been made available. These are 
zolmitriptan, naratriptan, rizatriptan, eletriptan, frovatriptan 
and almotriptan. All triptans are 5-HT1B/D serotonin recep-
tor agonists, acting in the cerebral vasculature to promote 
vasoconstriction and prevent the release of local vasoactive 
peptides responsible for inﬂ  ammation and generation of the 
pain stimulus (Ferrari and Saxena 1992). Clinically, triptans 
have been shown to provide rapid, effective and sustained 
pain relief and a reduction in the intensity or duration of 
associated symptoms.
A meta-analysis has been performed concerning 53 clinical 
trials with these triptans used orally for the acute treatment of 
migraine (Ferrari et al 2001). This concluded that between 
40% and 70% of patients treated with a triptan experienced a 
signiﬁ  cant reduction in pain severity after two hours, whereas 
between 10% and 25% are pain-free and remain pain-free for up 
to 24 hours. In terms of tolerability, naratriptan and almotriptan 
were associated with the lowest numbers of treatment-emergent 
adverse events. Dose-response relationships were observed 
for all triptans that had been evaluated at multiple doses. Very 
similar conclusions were drawn from a second meta-analysis 
evaluating 54 clinical trials which determined efﬁ  cacy in terms 
of numbers-needeed-to-treat (Oldman et al 2002). Another 
meta-analysis of 27 trials also used the numbers-needed-to-treat 
approach to assess cost-effectiveness, and found almotriptan 
to be the most cost-effective within the US healthcare system 
(Adelman and Belsey 2003). This has also been the conclu-
sion of a systematic review of pharmacoeconomic studies 
with the triptans (Loﬂ  and and Nash 2005). However, relative 
cost-effectiveness can vary considerably between different 
healhcare systems (Belsey 2004).
There are a number of factors entering into the choice 
of a given triptan for acute treatment, From the patient’s 
perspective, complete freedom from pain, rapid onset of 
action, no recurrence and absence of side effects are the most 
important criteria (Lanteri-Minet 2005). The TRIPSTAR 
study (Goadsby et al 2004; Lipton et al 2005a) has attempted 
to categorise efﬁ  cacy and tolerability attributes of triptans 
from extensive structured interviews with physicians and 
migraineurs. In a second step, individual drugs could be 
matched to this model. On the basis of such analyses, a 
stepwise heierarchy for the treatment of acute migraine with 
triptans can be proposed (Figure 4). The best-tolerated drugs 
should be used (almotriptan, frovatriptan or naratriptan) 
as a ﬁ  rst-line therapy. If these do not provide an adequate 
response, one of the other oral triptans should be tried. In case 
of continued treatment resistance, a nasal spray or injectable 
preparation should be proposed; This form is also proposed 
as ﬁ  rst line in children.
Prophylaxis of migraine
Migraine prophylaxis should be considered when acute 
treatment is insufﬁ  cient, either due to the severity of the 
headache disorder or to the ineffectiveness of treatment. 
Effective prophylaxis of migraine decreases recourse to 
acute treatment, thus reducing the risk of transformation 
to chronic headache and also decreases overall healthcare 
resource utilisation (Silberstein et al 2003). Guidelines 
proposed by the American College of Physicians (Snow et al 
2002) recommend that prophylaxis be initiated in patients 
with two or more migraine headaches per month that produce 
disability lasting three or more days per month, contraindi-
cations or non-response to acute treatment, the use of relief 
medication more than twice a week or who present with 
certain specified atypical migraine disorders. Broadly similar 
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Figure 3 Relief of migraine attack in 235 patients included in a comparative study of 
ketoprofen and zolmitriptan using a cross-over design (Dib et al 2002). Data are given 
as the percentage of the total number of attacks that were reduced in severity to mild 
or absent at two hours. Treatment groups are placebo (P), ketoprofen 75 mg (K75), 
ketoprofen 150 mg (K) and zolmitriptan 2.5 mg (Z). The asterisk indicates a signiﬁ  cant 
difference (p  0.0001; GEE model) between the bracketed groups.Therapeutics and Clinical Risk Management 2008:4(5) 1067
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recommendations have been published in a number of other 
national guidelines from, for example, Germany (Diener et al 
1998), the United Kingdom (Dowson et al 2002) and France 
(Geraud et al 2004).
The medication classes available for the prophylactic 
treatment of migraine are presented in Table 1. The speciﬁ  c 
prophylactic agents act by a variety of pharmacological 
mechanisms, and a large number of molecules have been 
evaluated in clinical trials of varying quality. A review of all 
these trials prepared by the Quality Standards Subcommittee 
of the American Academy of Neurology, however, identiﬁ  ed 
only four agents for which there was strong evidence of high 
efﬁ  cacy in the prophylaxis of migraine (Silberstein 2000). 
These four drugs were propranolol, timolol, amitriptyline 
and valproate.
Beta-blockers
β-Blockers represent the oldest, widest used and 
best-documented prophylactic treatment for migraine. The 
utility of propranolol was ﬁ  rst identiﬁ  ed quite serendipitously 
in 1972 (Weber and Reinmuth 1972) and since then has 
been the object of numerous clinical trials. A meta-analysis 
performed in 1991 of studies including 2403 patients included 
in placebo-controlled clinical trials reported a reduction of 
44% in the frequency of headaches in patients receiving 
propranolol compared to 16% in the placebo group (Holroyd 
et al 1991). A more recent evidence-based review performed 
for the Cochrane Collaboration (Linde and Rossnagel 2004) 
extending the analysis to over ﬁ  ve thousand patients included 
in 58 trials conﬁ  rmed the superiority of proranolol to placebo 
in the prophylaxis of migraine. No clear dose-response 
relationship is observed with propranolol, necessitating 
up-titration of the dose until an adequate therapeutic response 
is observed. In most patients, this is achieved at a dose of 
120–240 mg per day (Andersson and Vinge 1990). Proprano-
lol is considered to be the reference prophylactic treatment 
for migraine. Other β-blockers which have demonstrated 
superior efﬁ  cacy for migraine prophylaxis compared to 
placebo include metoprolol (Kangasniemi et al 1987; Steiner 
et al 1988), timolol (Tfelt-Hansen and Olesen 1984; Stellar 
et al 1984), altenolol (Forssman et al 1983; Johannsson et al 
1987) and nadolol (Freitag and Diamond 1984). Comparable 
efﬁ  cacy to propranolol has been shown for all four of these 
drugs (Kangasniemi and Hedman 1984; Olsson et al 1984; 
Tfelt-Hansen and Olesen 1984; Stensrud and Sjaastad 1980; 
Ryan 1984; Sudilovsky et al 1987). On the other hand, 
Nasal or sc 
triptans
Naratriptan, almotriptan or frovatriptan
Sumatriptan,  zolmitriptan
eletriptan or rizatriptan
First-line treatments
Second-line treatments
Third-line treatments
Figure 4 Treatment hierarchy for the acute treatment of migraine with triptans.
Table 1 Prophylactic treatments for migraine
β-Blockers Propranolol, metoprolol First-line treatment
α-Adrenergic drugs Indoramine, clonidine Evidence for efﬁ  cacy weak
Antiserotonergic drugs Methysergide, pizotifen, oxeterone
Certain calcium channel blockers Flunarizine Second-line treatment
Certain antidepressants Amitriptyline
Certain antiepileptic drugs Valproate, topiramate Second-line treatment
Ergot alkaloids Dihydroergotamine
Estrogens Estrodiol gel For menstrual migraineTherapeutics and Clinical Risk Management 2008:4(5) 1068
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β-blockers with partial agonist activity such as alprenolol 
(Ekbom 1975) or oxprenolol (Ekbom and Zetterman 1977), 
have not been shown to be beneﬁ  cial.
The most common side-effects observed with β-blockers 
include nausea, dizziness, fatigue, depression and insomnia, 
although these are generally not severe and do not lead to 
treatment discontinuation. In the meta-analysis of trials 
with propranolol (Holroyd et al 1991), the rate of study 
discontinuation for whatever reason was one in six.
Clonidine and other drugs acting 
at adrenoceptors
There have been sixteen controlled clinical trials of clonidine 
for the prophylaxis of migraine. Some of these have found 
small but signiﬁ  cant treatment effects, but most have not 
(Silberstein 2000). Two comparative studies suggest that 
clonidine is less efficacious than β-blockers (Kass and 
Nestvold 1980; Louis et al 1985).
Antiserotoninergic drugs
A number of small, relatively old clinical trials tested 
dihydroergotamine in the prophylaxis of migraine 
(Bonuso et al 1983; Bousser et al 1988; Langohr et al 
1988; Martucci et al 1983; Neuman et al 1986; Pradalier 
et al 1988). However, a recent randomized, parallel group 
study versus placebo in 363 patients (Pradalier et al 
2004a) which used a rigorous design following current 
clinical trial guidelines (Tfelt-Hansen et al 2000) did not 
reveal a statistically significant difference between the 
two treatments on the primary outcome measure (head-
ache frequency), although differences in favor of dihy-
droergotamine were observed for several of the secondary 
efficacy measures evaluated in the study. In spite of the 
paucity of evidence, dihydroergotamine is one of the 
treatment frequently used for the prevention of migraine, 
for example in France (Lanteri-Minet et al 2000).
Concerning other ergot derivatives, three cross-over 
studies (Frediani et al 1991; Bussone et al 1999; Micieli et al 
2001) have compared dihydroergocryptine to other prophy-
lactic treatments (propranolol, ﬂ  unarizine and dihydroergota-
mine). These studies all concluded that the drug may reduce 
headache frequency, but the absence of a comparison with a 
placebo group makes these studies difﬁ  cult to interpret.
Methysergide is a semi-synthetic derivative of ergot 
alkaloids that is a relatively selective antagonist at 5-HT2 
serotonin receptors. Methysergide was developed for the 
treatment of migraine in 1959 and the four clinical tri-
als that demonstrated superior efﬁ  cacy to placebo were 
performed in the 1960’s (Lance et al 1963; Shekelle and 
Ostfeld 1964; Pedersen and Moller 1966; Ryan 1968). More 
recently, comparative studies have been performed with 
propranolol (Steardo et al 1982), ﬂ  unarizine (Steardo et al 
1986) and 5-hydroxytryptophan (Titus et al 1986). However, 
methysergide has severally potentially serious side-effects, 
notably retroperitoneal or retropleural fibrosis (Elkind 
et al 1968). This is generally associated with long-term, 
uninterrupted administration and occurs in around one out of 
every ﬁ  ve thousand treated patients. For this reason, methy-
sergide is only recommended for severe migraine that has not 
responded to other prophylactic treatments (Silberstein 1998). 
When methysergide is used, the drug should be discontinued 
for three to four weeks after every six months of treatment.
Pizotifen (BC105, pizotyline) is extensively used in 
Europe as a prophylactic treatment for migraine. This 
serotonin receptor antagonist has been evaluated in several 
randomized, double-blind studies and shown to be superior 
to placebo for the prevention of migraine and to reduce 
utilisation of acute headache relief medication (Ryan 1968; 
Osterman 1977; Bellavance and Meloche 1990). Head-to-
head comparisons has shown its efﬁ  cacy to be similar to that 
of the β-blocker metoprolol (Vilming et al 1985). Pizotifen 
has also been demonstrated to be useful for the treatment 
of paediatric migraine in a small placebo-controlled study 
(Gillies et al 1986). Like other 5-HT2 receptor antagonists, 
use of pizotifen is associated with signiﬁ  cant weight gain, and 
treatment discontinuation rates for side-effects are high.
Other 5-HT receptor antagonists that have been evaluated 
in the prevention of migraine include cyproheptadine, lisuride, 
oxeterone, iprazochrome, 5-hydroxytryptophan (oxitriptan) 
and tropisetron. With the exception of tropisetron, these 
agents are antagonists at 5-HT2 receptors, although most 
of them are relatively aspeciﬁ  c and also act at other mono-
amine receptors or ion channels. Cyproheptadine has been 
found to decrease the frequency of migraine attacks in a 
small early study (Lance et al 1970) and has subsequently 
become widely-used for prevention of migraine headaches 
in children (Bille et al 1977). Quite recently, a randomized, 
double-blind trial compared treatment with placebo, cypro-
heptadine, propranolol and the combination of the two active 
drugs (Rao et al 2000). Not only did this study conﬁ  rm the 
beneﬁ  t offered by cyproheptadine compared to placebo, but 
also indicated that the association of the two drugs resulted 
in a larger reduction in headache frequency than did the use 
of either drug alone. Lisuride was evaluated in two double-
blind, placebo-controlled clinical trials (Somerville and 
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stems from four small, double-blind studies performed in 
Switzerland in the late ‘70s (de Coster 1976; Wasserfallen 
1976; Dufresne 1978; Florence 1978). Two randomized, 
placebo-controlled, double-blind studies of iprazochrome 
found the drug to be superior to placebo for the prevention 
of migraine (Kozubski and Prusinski 1999; Osterman 1977); 
in the ﬁ  rst of these, pizotifen was also studied and found to 
be more effective than iprazochrome. Placebo-controlled 
studies with 5-hydroxytryptophan have failed to provide 
convincing evidence of efﬁ  cacy (De Benedittis and Massei 
1985; Santucci et al 1986) and comparative studies with 
methysergide (Titus et al 1986) and propranolol (Maissen 
and Ludin 1991) have found 5-hydroxytryptophan to be 
less effective than these two drugs. Two large, random-
ized, double-blind, placebo-controlled trials with the 5-HT3 
receptor antagonist tropisetron have yielded inconclusive 
results (Ferrari et al 1991).
Calcium channel blockers
Calcium channel blocking drugs have evoked much interest 
in the prophylactic treatment of migraine due to their 
vasodilator effects in the cerebral vasculature (Montastruc 
and Senard 1992). However, the only such drug that has 
demonstrated unequivocal efﬁ  cacy is ﬂ  unarizine, and it is 
debatable whether this property is related to calcium channel 
blockade at all. It has been suggested that a neuronal rather 
than a vascular action underlies its beneﬁ  cial effects in 
migraine (Olesen 1990). This drug has been evaluated in nine 
placebo-controlled clinical trials, although several of these 
are small or of poor quality. A meta-analysis of the most 
robust of these trials (Reveiz-Herault et al 2003) concluded 
that treatment ﬂ  unarizine resulted in a greater reduction in 
headache frequency than placebo. Comparative trials have 
generally demonstrated a similar effect size as that obtained 
with propranolol (Lucking et al 1988; Ludin 1989; Gawel 
et al 1992; Diener 1997) or metoprolol (Grotemeyer et al 
1988; Sorensen et al 1991). One small study which investi-
gated combination therapy with propranolol and ﬂ  unarizine 
failed to demonstrate superior efﬁ  cacy for the combination 
compared with monotherpay with either drug alone (Bordini 
et al 1997).
The side effects described for treatment with ﬂ  unarizine 
are somnolence, weight gain, and, in less frequently, depres-
sion. Treatment discontinuation rates due to side-effects 
have been high in many of the clinical trials. Due to the 
relatively poor side-effect proﬁ  le of ﬂ  unarizine compared to 
β-blockers, the use of this drug should be reserved for second-
line treatment (Montastruc and Senard 1992). Dotarizine is 
an analogue of ﬂ  unarizine which has showed preliminary 
evidence of efﬁ  cacy for the prophylaxis of migraine (Galiano 
et al 1993).
Concerning other classes of calcium channel blocker, 
studies with dihydropyridines have been inconclusive 
(Montastruc and Senard 1992). Nifedipine was found to offer 
no beneﬁ  t over placebo in two randomized, double-blind 
clinical trials (McCarthy and Peroutka 1989; Shukla et al 
1995), whereas nicardipine (Leandri et al 1990) was reported 
to be effective. For nimodipine, two positive (Gelmers 1983; 
Havanka-Kanniainen et al 1985), and three negative (Ansell 
et al 1988; MINES 1989a, 1989b) placebo-controlled stud-
ies have been reported. Study sizes were rather small in all 
cases. Preliminary evidence for the efﬁ  cacy of verapamil 
has come from three small placebo-controlled trials, none 
of which included more than twenty-ﬁ  ve patients (Solomon 
1989). Diltiazem has not been evaluated in randomized, 
double-blind controlled studies. The most recently evaluated 
calcium channel blocker is cyclandelate, for which three 
placebo-controlled trials have been performed, two of which 
included over 200 patients (Diener et al 1996; Diener et al 
2001) and did not demonstrate superior efﬁ  cacy to placebo 
in preventing headaches. The third, smaller (n = 25) study 
did ﬁ  nd cyclandelate to be more efﬁ  cacious than placebo 
(Siniatchkin et al 1998).
Antiepileptic drugs
Although interest in the potential of antiepileptic drugs for 
the treatment of migraine headache goes back over thirty 
years (Rompel and Bauermeister 1970), there has been a 
renewal of interest in such drugs over the last decade. Most 
of the large randomized clinical trials in migraine prophy-
laxis which have used current standards of clinical trial 
methodology (IHSCCT 1991) have concerned this class of 
drug, which represents the principal innovation in the ﬁ  eld for 
over twenty-ﬁ  ve years. Antiepileptic drugs reduce neuronal 
excitability and thus reduce the cortical spreading depression 
that is believed to be an early event in the development of 
migraine headache (Welch 2003). A number of studies using 
transcranial magnetic stimulation or magnetoencephalogra-
phy (Bowyer et al 2005; Mulleners et al 2002) have shown 
that antiepileptic drugs do effectively reduce cortical hyper-
excitability in patients with migraine.
A number of antiepileptic drugs was tested over the past 
twenty years (Krymchantowski et al 2002; Silberstein and 
Goadsby 2002; Chronicle and Mulleners 2004; Young et al 
2004). These include valproate, topiramate, gabapentin, 
lamotrigine, carbamazepine, clonazepam, tiagabine, Therapeutics and Clinical Risk Management 2008:4(5) 1070
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leviracetam and zonisamide. Recent, large-scale controlled 
trials are however limited to the ﬁ  rst four drugs, and only 
valproate and topiramate have been approved for the prophy-
laxis of acute migraine in some countries. Studies performed 
with tiagabine (Drake et al 1999; Freitag et al 1999), leve-
tiracetam (Drake et al 2001; Krusz 2001a) and zonisamide 
(Drake et al 2001; Krusz 2001b) did not include a control 
group and thus allow no conclusions to be drawn as to their 
real clinical beneﬁ  t.
The ﬁ  rst clinical trial dates from 1970, when Rompel and 
Bauermeister (1970) evaluated the efﬁ  cacy of carbamaze-
pine in a randomized, placebo-controlled, cross over study, 
and observed an improvement in 84% of patients during 
treatment with carbamazepine compared to 27% during the 
placebo phase, and a corresponding reduction in the number 
of migraine attacks from 186 under placebo to 30 under 
carbamazepine.
The ﬁ  rst study evaluating the efﬁ  cacy of valproate, and 
using a placebo-controlled double-blind randomized cross-over 
design in twenty-nine patients (Hering and Kuritzky 1992). 
Patients received a low dose of valproate (400 mg) for eight 
weeks. Reduction of the frequency, severity and duration of 
migraine attacks was observed in 86.2% of the patients stud-
ied. A number of subsequent randomized, controlled studies 
have valproate in the prophylaxis of migraine headache 
(Jensen et al 1994; Mathew et al 1995; Klapper 1997; Freitag 
et al 2002), and concluded that this drug is an efﬁ  cacious, 
well-tolerated and easy-to-use medication. Notably, the 
ﬁ  ndings were replicated in a much larger study including 
107 patients and using a parallel-group design (Mathew et al 
1995). A reduction of at least 50% in headache frequency 
compared to baseline was observed in 48% of patients receiv-
ing valproate compared to 14% of those receiving placebo. 
The severity of residual headaches was also reduced in the 
valproate treatment group. However, there was a higher rate 
of adverse events and of treatment discontinuation in patients 
receiving valproate. A dose-ranging study comparing ﬁ  xed 
doses of 500 mg, 1000 mg, or 1500 mg with placebo (Klapper 
1997) showed similar efﬁ  cacy between all three doses, and 
recommended that the 500 mg/day dose should be used in 
most patients. A subsequent study, in which responses were 
related to plasma levels of valproate, also concluded that 
for most patients, doses over 600 mg/day would provide no 
additional beneﬁ  t over lower doses.
It should be noted that intravenous valproate has also 
been evaluated in several randomized, controlled studies 
(Edwards et al 2001; Tanen et al 2003; Leniger et al 
2005) for the acute treatment of migraine, following 
the publication of an extensive uncontrolled case series 
suggesting the interest of such a treatment (Mathew et al 
2000). Although efﬁ  cacious, it appeared less active than 
intravenous lysine-acetylsalicylic acid or prochlorpera-
zine. The tolerability and commodity of use of intravenous 
valproate in this indication are obviously inferior compared 
to triptans or NSAIDS and this treatment is unlikely to be 
of widespread use.
Although treatment with valproate is generally well-tolerated, 
this drug is associated with an elevated teratogenic risk (Tomson 
and Battino 2005). In patients with epilepsy, this risk has been 
estimated in a number of dedicated retrospective and prospec-
tive surveys. For example, in a recent analysis of data from the 
Swedish Medical Birth Registry and the Swedish Registry of 
Congenital Malformations, the rate of major malformations in 
neonates exposed to valproate in utero was 9.7% compared to 
1.0% in the Swedish general population (Wide et al 2004). There 
is some evidence that this risk is dose-related, being particularly 
high with valproate doses over 800–1000 mg/day. In patients 
with migraine, of whom women of child-bearing age represent 
the majority, this risk clearly needs to be taken into account in 
assessing the risks and beneﬁ  ts of treatment with valproate. 
Unlike what is observed for epilepsy, where this may be the 
only drug that offers complete seizure freedom, in migraine, 
valproate is just one of a number of agents that offers a similar 
level of headache relief.
The most data on the utility of antiepileptic drugs 
in the prophylaxis of migraine has been obtained for 
topiramate. The interest of this drug was first suggested 
in a series of open-label studies (Krusz and Scott 1999; 
Mathew et al 2002; Schuaib et al 1999; Von Seggern et al 
2002; Young et al 2002) and subsequently confirmed in 
two randomized controlled pilot studies (Storey et al 
2001; Edwards et al 2003).
Two large pivotal randomized Phase III clinical trials 
were performed and the results used to obtain marketing 
authorisation for topiramate. These evaluated three doses of 
topiramate (50 mg/day, 100 mg/day and 200 mg/day) in over 
900 adult subjects using an identical design (Brandes et al 
2004; Silberstein et al 2004). These studies demonstrated a 
reduction in the monthly frequency of migraine headaches 
of 30% to 50% following initiation of topiramate treatment 
(Figure 5). The effect of topiramate was dose-related and 
usually was observable within the ﬁ  rst month of treatment. 
Since then, several other randomized, controlled studies 
have generated data largely consistent with the results of the 
pivotal studies (Silvestrini et al 2003; Diener et al 2004b; 
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However, a number of potentially serious side-effects are 
associated with topiramate (Jones 1998), and it is important to 
consider safety issues carefully before and during treatment 
of patients with migraine with this antiepileptic drug. Many 
of these side-effects are related to inhibition of carbonic 
anhydrase, including metabolic acidosis, formation of kidney 
stones, acute myopia associated with secondary angle clo-
sure glaucoma, paraesthesia and oligohidrosis. In addition, 
impairments of cognitive function (slowing of thought pro-
cesses) and fatigue are commonly reported. Topiramate use is 
also associated with signiﬁ  cant weight loss, which may also 
be detrimental to self-image and quality of life. The incidence 
of these side-effects appears to be dose-related and can be 
mitigated by slowly titrating the dose upwards.
Two randomized, placebo-controlled studies have 
assessed the efﬁ  cacy and safety of gabapentin in the prophy-
laxis of migraine. One study evaluated doses of 900 mg/day 
to 2400 mg/day and included 143 subjects (Mathew et al 
2001), whilst the other evaluated a ﬁ  xed dose of 1200 mg/day 
in 63 subjects (Di Trapani et al 2000). The larger study 
demonstrated a higher proportion of patients achieving a 
reduction in the monthly migraine rate of at least 50% in 
the gabapentin-treated patients compared to those receiv-
ing placebo, and a signiﬁ  cant reduction in the frequency 
and severity of migraine headaches was reported in the 
smaller study. Nonetheless, somnolence and dizziness were 
observed in a signiﬁ  cant minority of patients. A subsequent 
randomized, open-label study found essentially similar 
ﬁ  ndings (Jimenez-Hernandez et al 2002).
Lamotrigine has been studies in three open-label studies 
(D’Andrea et al 1999; Lampl et al 1999; Pascual et al 2004) 
and one randomized, placebo controlled study (Steiner 
et al 1997). Although the open-label studies suggested that 
lamotrigine could be of beneﬁ  t, particularly in relieving aura, 
the placebo-controlled study, which included 110 patients, 
found no evidence that the efﬁ  cacy of lamotrigine was 
superior to placebo.
Clonazepam has been evaluated in a small, random-
ized, placebo-controlled double-blind, cross-over study 
(Stensrud and Sjaastad 1979). This alternated four-week 
treatment-free run-in periods with four-week treatment 
periods where the patients received placebo, clonazepam 
1 mg or clonazepam 2 mg. A signiﬁ  cant reduction in head-
ache frequency compared to the run-in period was observed 
for the two clonazepam-treatment periods but not for the 
placebo period.
Compared with β-blockers, randomized clinical trials 
of valproate (Kaniecki 1997) and topiramate (Diener 
et al 2004b) have shown these two drugs to have simi-
lar efﬁ  cacy to propranolol, although the β-blocker was 
better tolerated. Due to this difference in tolerability, 
antiepileptic drugs should be considered principally as 
second-line treatments in patients who have failed to 
respond adequately to β-blockers. There is little informa-
tion on the utility of combining antiepileptic drugs and 
β-blockers. An open-label study which evaluated the 
combination of propranolol or nadolol with valproate 
in 52 subjects who had failed to respond to the individual 
drugs in monotherapy (Pascual et al 2003). This study 
demonstrated that over half the treated subjects responded 
to the combination treatment. A second open-label study 
investigated add-on treatment with topiramate in patients 
who responded inadequately to current prophylactic 
treatment, principally with propranolol or flunarizine 
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Figure 5 Efﬁ  cacy of topiramate in the prophylaxis of migraine. Three different doses of topiramate (TPM; 50 mg/day, 100 mg/day, and 200 mg/day) are compared with placebo 
(Pbo). Data represent the change in monthly migraine frequency compared to a pre-treatment baseline period. The asterisks indicate a statistically signiﬁ  cant difference from 
placebo (*p  0.01; **p  001). Data are taken from Brandes and colleagues (2004) (grey columns) and Silberstein and colleagues (2004) (black columns).Therapeutics and Clinical Risk Management 2008:4(5) 1072
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(Martinez et al 2003). Again, headache frequency 
decreased after initiation of combination treatment. 
These interesting observations deserve conﬁ  rmation in 
randomized, double-blind studies.
Antidepressants
The utility of certain antidepressants for the prophylaxis of 
migraine dates from the only 1970s (Gomersall and Stuart 
1973). The most widely studied antidepressant is amitrip-
tyline and this agent appears to be the most efﬁ  cacious 
(Colombo et al 2004). It is possible that amitriptyline is 
active in the prophylaxis of migraine by virtue of an action 
at voltage-sensitive ion channels controlling neuronal excit-
ability. However, this drug causes sedation which may not be 
desirable in patients taking this drug every day for migraine 
prophylaxis. In this respect, other antidepressants with a more 
acceptable side-effect proﬁ  le may be preferred. For example, 
venlafaxine was shown to be reduce headache frequency in a 
retrospective case series (Adelman et al 2000) and has since 
shown similar efﬁ  cacy to amitriptyline and superior efﬁ  cacy 
to placebo in two recent randomized, double-blind studies 
(Bulut et al 2004; Ozyalcin et al 2005).
Other older antidepressants for which there is some evi-
dence for efﬁ  cacy in the prophylaxis of migraine include 
clomipramine (Noone 1980; Langohr et al 1985), opipramol 
(Jacobs 1972) and mianserin (Monro et al 1985). However, 
these relatively old studies generally included small numbers 
of patients, were not always double-blinded, and did not use the 
design and outcome criteria currently recommended for ran-
domized clinical trials in migraine (Tfelt-Hansen et al 2000).
The utility of selective-serotonin reuptake inhibitors 
in the prophylaxis of migraine is much less clear. Early 
studies performed in the 1980’s in Scandinavia failed to 
demonstrate clear efﬁ  cacy for femoxitine (Andersson and 
Petersen 1981; Zeeberg et al 1981; Kangasniemi et al 1983; 
Orholm et al 1986) and more recent studies with sertraline 
(Landy et al 1999) and citalopram have also been disappoint-
ing (Rampello et al 2004). On the other hand, there is some 
weak evidence for the efﬁ  cacy of ﬂ  uvoxamine (Bank 1994) 
and ﬂ  uoxetine (Adly et al 1992; Saper et al 1995; Steiner 
et al 1998; d’Amato et al 1999).
Of particular interest is the use of amitriptyline, and 
potentially other antidepressants, in the treatment of chronic 
daily headache. A meta-analysis of thirty-eight clinical 
trials (Tomkins et al 2001) concluded that all classes of 
antidepressant drug evaluated (tricyclics, selective serotonin 
reuptake inhibitors and serotonin receptor antagonists) were 
all effective in reducing the frequency of both migraine-type 
and tension-type chronic daily headaches with an effective 
size that was considered as large. This allowed a reduction 
in the use of analgesics as headache relief medication. Since 
analgesic use is considered to be an important factor in the 
development and maintenance of chronic headaches, and 
a major determinant of poor prognosis, prophylaxis with 
antidepressants may improve clinical outcome over the 
long-term as well as reducing headache frequency in the 
short-term.
Hormone therapy for menstrual migraine
Oral contraception with progestins can be effective in 
reducing the frequency of menstrual migraine headaches 
(Bradley et al 1968; Somerville and Carey 1970), presum-
ably by suppression of the menstrual cycle. However, oral 
contraceptive regimens using continuous progestin exposure 
seem interesting but are no longer widely used, and current 
standard oral contraceptives have not been found to be par-
ticularly efﬁ  cacious (Silberstein and Merriam 1999). Use of 
long-acting estrogen preparations such as gels (de Lignieres 
et al 1986; Dennerstein et al 1988; MacGregor and Hackshaw 
2002; MacGregor et al 2006) or patches (de Lignieres and 
Bousser 1992; Pfaffenrath 1993; Pradalier et al 2004b) have 
also been reported to be effective for migraine prophylaxis 
and may be more suitable formulations in this indication. 
These estrogens initiated at the end of the luteal phase and 
maintained until the end of the menstrual period compensate 
for the rapid fall of endogenous estrogen concentrations that 
is thought to precipitate migraine headaches. Two small 
clinical trials of phytoestrogens (Burke et al 2002; Ferrante 
et al 2004) suggested that these agents may also be effective 
in the treatment of menstrual migraine.
Conclusions
Advances in our understanding of the pathophysiology of 
migraine have resulted in important breakthroughs in treat-
ment. Notably, understanding of the role of serotonin in the 
cerebrovascular circulation led to the development of triptans 
for the acute relief of migraine headaches, and the identiﬁ  -
cation of cortical spreading depression as an early central 
event associated wih migraine has brought renewed interest 
in antiepileptic drugs for migraine prophylaxis.
Nevertheless, several important questions remain. Firstly, 
while it is increasingly recognized that migraine is not a 
single disease but rather a syndrome that can manifest itself in 
a variety of pathological conditions, the consequences of this 
for treatment are not understood. Clinical research needs to be 
devoted to identifying which sort of patients beneﬁ  t best from Therapeutics and Clinical Risk Management 2008:4(5) 1073
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which treatments, particularly in the ﬁ  eld of prophylaxis. One 
possible approach that merits exploration is to try and match 
prophylactic treatments to particular patterns of precipitating 
factors, as has already proved successful for the treatment 
of menstrual migraine In this respect, the proposal of four 
types of migraine (adrenergic, serotoninergic, menstrual, and 
muscular) may contribute to the optimisation of migraine 
prophylaxis.
The interest of stratifying treatment strategies by headache 
severity is also at an early stage. Studies such as DISC (Lipton 
et al 2000b; Sculpher et al 2002) suggest that this could be a 
useful approach, but treatment stratiﬁ  cation remains under-
exploited in routine care of patients with migraine. Further 
prospective studies would help characterising patient severity 
groups that would beneﬁ  t from particular strategies.
Treatment resistance is frequent with both acute and 
prophylactic treatments of migraine. Even with triptans, 
probably the most effective class of antimigraine drug, up to 
one-third of patients fail to respond adequately. The reasons 
underlying treatment resistance need to be better understood, 
and strategies identiﬁ  ed to avoid serial treatment failures 
when the patient ﬁ  rst comes to the clinic.
Moreover, there is a lack of information on the beneﬁ  t 
of combination treatment using different drug classes. This 
approach may be of particular use in patients with more 
severe hedaches and in those showing mixed headache 
types. In this respect, and bearing in mind potential artefacts 
due to the open-label design of the study, the results of the 
combination study with propranolol and valproate imply 
that these two agents can be used in association to provide 
greater efﬁ  cacy in particular patients. Further studies such as 
this using a randomized, double-blind design are required to 
provide the data necessary to orientate treatment decisions 
about combinations of migraine prophylaxis agents.
Finally, little is known about long-term outcome in treated 
migraine. It is possible that appropriate early prophylaxis may 
modify the long-term course of the disease and avoid late 
complications, as has been shown, for example, in another 
paroxystic neurological condition, epilepsy. This is particu-
larly relevant for antiepileptic drugs that are thought to be of 
beneﬁ  t in migraine by an action on cortical excitability. If this 
is the case, then early aggressive migraine prophylaxis may be 
merited. Although medication overuse can be a predisposing 
factor to developing a chronic headache syndrome, risk 
thresholds remain poorly quantiﬁ  ed, particularly for speciﬁ  c 
acute migraine treatments such as the triptans.
Although migraine is much better deﬁ  ned than it was 
twenty years ago, and more efﬁ  cacious and better tolerated 
treatments are on offer, there is still a long way to go before 
we can provide patients with individualized and rational 
long-term therapeutic management strategies that take into 
account the heterogeneity of the migraine condition and its 
variable clinical course.
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